Tango Therapeutics TNGX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -178.4%+168pp | -346.1%-33.5pp | -312.6%+134pp | -446.8%-290pp | |
| Net margin | -162.9%+147pp | -309.7%-31.2pp | -278.5%+157pp | -435.1%-278pp | |
| Returns | |||||
| Return on equity | -37.2%+20.3pp | -57.6%-17.1pp | -40.5%-4.1pp | -36.4%-6.0pp | |
| Return on invested capital | -51.3%+23.4pp | -74.7%-24.4pp | -50.3%+0.9pp | -51.2%-16.9pp | |
| Efficiency | |||||
| Asset turnover | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Liquidity | |||||
| Current ratio | 16.3×+9.3× | 7×-0.6× | 7.5×+0.8× | 6.8×-5.3× | |
| Leverage | |||||
| Debt-to-equity | 0.1×-0.1× | 0.2×0.0× | 0.1×0.0× | 0.2×+0.2× | |
| Per Share | |||||
| Book value per share | $2.98+63.1% | $1.83-31.7% | $2.68-5.8% | $2.84-48.8% | |
| Valuation | |||||
| Market capitalization | $1.19B+259% | $331.92M-65.5% | $962.51M+50.9% | $637.79M-33.5% | |
| Price / sales | 19.1×+11.2× | 7.9×-18.5× | 26.4×+0.7× | 25.7×-0.2× | |
| Price / book | 3.4×+1.8× | 1.7×-2.1× | 3.8×+1.2× | 2.6×-0.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Tango Therapeutics's ratios come from?
- Every ratio is computed from Tango Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
